Eli Lilly | LLY - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Abbott USD 299M 231M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Baxter International USD 78M 20M 2026-03
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Coherus Biosciences USD 2.25M 76K 2025-12
Drreddys Laboratories INR 1.06B 113M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Glaxosmithkline GBP 192.73M 14.79M 2026-03
J&J USD 43M 25M 2026-03
Medtronic USD 186M 10M 2026-06
Merck USD 525M 46M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Novartis USD 281M 8M 2025-09
Novo Nordisk DKK 1.5B 28M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 667M 4M 2026-06
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 13.94M 2.52M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 287M 109M 2026-06
Sanofi EUR -25M 99.78M 2025-12
United Therapeutics USD 2.9M 200K 2026-06
Zoetis USD 61M 1000K 2026-06